MRI are Class II devices and until last year exemptions for IDE applications and for not obtaining written informed consent specifically excluded devices that by design or intent deposit energy in humans (regardless of overall study risk. Last year the FDA finally extended some power to IRBs to harmonize with HHS research regulations which have allowed IRBs to waive consent for minimal risk studies for a long time. But FDA directing you to an IRB rather than both an IRB and the FDA itself doesn't mean you're not dealing with an IRB.
FDA and human subject protections come from different laws with different legislative authority. The regulations are not the same except to the extent that the agencies themselves work to harmonize things. If you are doing anything covered by FDA you must follow FDA's regulations in addition to any other applicable human subjects research regulations. And because MRI scanners are Class II regulated devices it means that people are being scanned with a doctor's permission, an IRB's permission or the FDA's direct permission.
FDA "doesn't care" about SAR to the extent that they have published guidance that if you operate an approved MRI scanner within normal operating mode (which are settings defined by IEC that do not necessitate medical supervision), then the FDA will not automatically consider use of the scanner itself to elevate a study's risk (in the way that using something like a CT scanner with ionizing radiation would). Risk determination goes beyond whether or not the MRI itself is a risk though. For example a research study that diverts patients to MRI in a way that delays care in an emergent situation (say testing experimental sequences for stroke detection) is unlikely to overall qualify as minimal risk even if the scanner operates in normal mode because of other non-MRI risks associated with the study procedures.
Retrospective use of de-identified or anonymized medical records that already exist are of course a different thing because the risks to the patient are primarily privacy risks.
And you are correct the actual FDA labels of all the AI crap that's coming out are jokes compared to what a lot of sales bullshitters promise. But you better believe all the data submitted to the FDA by the MRI manufacturers support their accelerated acquisitions that use deep learning recons follow FDA's clinical trials regulations.
I don't disagree with anything you're saying necessarily, but a lot of people are conflating my statement of IRB exemption with having an explicit IRB authorization. I guess more to my point is people seem to be failing to understand the role of retrospective research (and I will easily concede that different institutions have different legal interpretations) and how it's an important part of research. Don't get me wrong, you absolutely still have regulations about what you can and cannot do with that data, but saying you need an IRB for everything doesn't match the reality that I've seen first hand.
That said, there's plenty of buying and selling of radiological images for industry development on the second hand market. Now where the line of "research" vs. "industrial" work is, well that's something I would leave to legal council. But as you said any sort of "altering" of clinical outcomes is a clear IRB is required zone like DL based recon.
FDA and human subject protections come from different laws with different legislative authority. The regulations are not the same except to the extent that the agencies themselves work to harmonize things. If you are doing anything covered by FDA you must follow FDA's regulations in addition to any other applicable human subjects research regulations. And because MRI scanners are Class II regulated devices it means that people are being scanned with a doctor's permission, an IRB's permission or the FDA's direct permission.
FDA "doesn't care" about SAR to the extent that they have published guidance that if you operate an approved MRI scanner within normal operating mode (which are settings defined by IEC that do not necessitate medical supervision), then the FDA will not automatically consider use of the scanner itself to elevate a study's risk (in the way that using something like a CT scanner with ionizing radiation would). Risk determination goes beyond whether or not the MRI itself is a risk though. For example a research study that diverts patients to MRI in a way that delays care in an emergent situation (say testing experimental sequences for stroke detection) is unlikely to overall qualify as minimal risk even if the scanner operates in normal mode because of other non-MRI risks associated with the study procedures.
Retrospective use of de-identified or anonymized medical records that already exist are of course a different thing because the risks to the patient are primarily privacy risks.
And you are correct the actual FDA labels of all the AI crap that's coming out are jokes compared to what a lot of sales bullshitters promise. But you better believe all the data submitted to the FDA by the MRI manufacturers support their accelerated acquisitions that use deep learning recons follow FDA's clinical trials regulations.